Development of HBsAg-binding aptamers that bind HepG2.2.15 cells via HBV surface antigen

Virologica Sinica

Volumn 25, Issue 1, 2010, Pages 27-35

  Liu, Jia ^a   Yang, Yan ^b   Hu, Bin ^a   Ma, Zhi Yong ^a   Huang, Hong Ping ^b   Yu, Yuan ^b   Liu, Shen Pei ^b   Lu, Meng Ji ^b,c   Yang, Dong Liang ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Aptamer; HBsAg; Hepatitis B virus (HBV); Hepatocytes; Systematic evolution of ligands by exponential enrichment (SELEX)

Indexed keywords

APTAMER; HBS A22 APTAMER; HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING CELL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CELL STRAIN HEPG2; CELL STRAIN HEPG2.2.15; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; GENETIC SELECTION; HEPATITIS B VIRUS; MOLECULAR LIBRARY; NONHUMAN; PROTEIN BINDING; RNA SEQUENCE; VIRUS ISOLATION;

APTAMERS, NUCLEOTIDE; CELL LINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATOCYTES; HUMANS; PROTEIN BINDING; SELEX APTAMER TECHNIQUE; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 77249114413     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-010-3091-7     Document Type: Article

References (37)

1. L. C. Bock L. C. Griffin J. A. Latham, et al. 1992 Selection of single-stranded DNA molecules that bind and inhibit human thrombin Nature 355 6360 564 566 10.1038/355564a0 1:CAS:528:DyaK38XktVejs7Y%3D 1741036
2. E. N. Brody L. Gold 2000 Aptamers as therapeutic and diagnostic agents J Biotechnol 74 1 5 13 1:CAS:528:DC%2BD3cXivFSiu7c%3D 10943568
3. J. A. Chapman C. Beckey 2006 Pegaptanib: A novel approach to ocular neovascularization Ann Pharmacother 40 7-8 1322 1326 1:CAS:528: DC%2BD28XptVehsrk%3D 16849623
4. C. M. Chu Y. F. Liaw 1987 Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis Gastroenterology 92 220 225 1:STN:280: DyaL2s%2FlsFWjsQ%3D%3D 3536652
5. T. C. Chu K. Y. Twu A. D. Ellington, et al. 2006 Aptamer mediated siRNA delivery Nucleic Acids Res 34 10 e73 10.1093/nar/gkl388 16740739 (Pubitemid 44540445)
6. G. J. Connell M. Illangesekare M. Yarus 1993 Three small ribooligonucleotides with specific arginine sites Biochemistry 32 21 5497 502 10.1021/bi00072a002 1:CAS:528:DyaK3sXisV2qs7g%3D 8504070
7. J. L. Dienstag 2006 Looking to the future: new agents for chronic hepatitis B Am J Gastroenterol 101 S19 S25 10.1111/j.1572-0241.2006.00377.x 1:CAS:528:DC%2BD28XitFWisL0%3D 16448448 (Pubitemid 43381697)
8. A. D. Ellington J. W. Szostak 1990 In vitro selection of RNA molecules that bind specific ligands Nature 346 6287 818 822 10.1038/346818a0 1:CAS:528:DyaK3MXitVGgsw%3D%3D 1697402 (Pubitemid 20272100)
9. R. G. Gish 2005 Current treatment and future directions in the management of chronic hepatitis B viral infection Clin Liver Dis 9 541 565 10.1016/j.cld.2005.08.005 16207563 (Pubitemid 41406387)
10. R. Guan 2005 Treatment of chronic hepatitis B infection using interferon Med J Malaysia 60 28 33 16108170
11. B. J. Hicke C. Marion Y. F. Chang, et al. 2001 Tenascin-C aptamers are generated using tumor cells and purified protein J Biol Chem 276 52 48644 48654 10.1074/jbc.M104651200 1:CAS:528:DC%2BD38XktlaqsA%3D%3D 11590140
12. B. J. Hicke A. W. Stephens 2000 Escort aptamers: a delivery service for diagnosis and therapy J Clin Invest 106 8 923 928 10.1172/JCI11324 1:CAS:528:DC%2BD3cXnsVeisLk%3D 11032850
13. S. D. Jayasena 1999 Aptamers: an emerging class of molecules that rival antibodies in diagnostics Clin Chem 45 9 1628 1650 1:CAS:528:DyaK1MXlvFertrk%3D 10471678
14. R. D. Jenison S. D. Jennings D. W. Walker, et al. 1998 Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion Antisense Nucleic Acid Drug Dev 8 4 265 279 1:CAS:528:DyaK1cXlvFGgur0%3D 9743465
15. A. Khaled S. Guo F. Li, et al. 2005 Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology Nano Letters 5 9 1797 1808 10.1021/nl051264s 1:CAS:528:DC%2BD2MXpvFCiuro%3D 16159227 (Pubitemid 41396168)
16. T. Kojima 1982 Immune electron microscopic study of hepatitis B virus associated antigens in hepatocytes Gastroenterol Jpn 17 559 575 1:STN:280:DyaL3s7jtlSlug%3D%3D 7160600
17. C. J. Liu J. M. Liou D. S. Chen, et al. 2005 Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections J Formos Med Assoc 104 783 791 16496056
18. P. Marcellin T. Asselah N. Boyer 2005 Treatment of chronic hepatitis B J Viral Hepat 12 333 345 10.1111/j.1365-2893.2005.00599.x 1:STN:280: DC%2BD2MzjsV2jug%3D%3D 15985003 (Pubitemid 40961472)
19. J. O. McNamara 2nd E. R. Andrechek Y. Wang, et al. 2006 Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat Biotechnol 24 8 1005 1015 10.1038/nbt1223 1:CAS:528:DC%2BD28XnvVygt7o%3D 16823371 (Pubitemid 44215395)
20. E. W. Ng D. T. Shima P. Calias, et al. 2006 Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat Rev Drug Discov 5 2 123 132 10.1038/nrd1955 1:CAS:528:DC%2BD28Xhslaqur8%3D 16518379
21. P. Ocama C. K. Opio W. M. Lee 2005 Hepatitis B virus infection: current status Am J Med 118 1413 10.1016/j.amjmed.2005.06.021 16378788 (Pubitemid 41832336)
22. S. Onishi T. Saibara K. Ito 1985 Hepatitis B surface antigen specific cytotoxic T lymphocyte activity in hepatitis B virus infection Gastroenterol Jpn 20 330 337 1:STN:280:DyaL28%2FjtFSquw%3D%3D 3876961
23. N. C. Pagratis C. Bell Y. F. Chang, et al. 1997 Potent 2-amino-, and 2-fluoro-2-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor Nat Biotechnol 15 1 68 73 10.1038/nbt0197-68 1:CAS:528:DyaK2sXislGqsw%3D%3D 9035109
24. R. P. Perrillo 2005 Current treatment of chronic hepatitis B: benefits and limitations Semin Liver Dis 25 20 28 10.1055/s-2005-915647 1:CAS:528:DC%2BD2MXhtV2ju7%2FI 16103978 (Pubitemid 41254590)
25. A. Rhodes A. Deakin J. Spaull, et al. 2000 The generation and characterization of antagonist RNA aptamers to human oncostatin M J Biol Chem 275 37 28555 28561 10.1074/jbc.M002981200 1:CAS:528:DC%2BD3cXms1Cqsro%3D 10882721
26. A. Rhodes N. Smithers T. Chapman, et al. 2001 The generation and characterisation of antagonist RNA aptamers to MCP-1 FEBS Lett 506 2 85 90 10.1016/S0014-5793(01)02895-2 1:CAS:528:DC%2BD3MXnsVSmtb8%3D 11591377 (Pubitemid 32925205)
27. A. Rivkin 2005 A review of entecavir in the treatment of chronic hepatitis B infection Curr Med Res Opin 21 1845 1856 10.1185/030079905X65268 1:CAS:528:DC%2BD28XnvVQ%3D 16307706 (Pubitemid 41667253)
28. J. Ruckman L. S. Green J. Beeson, et al. 1998 2-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J Biol Chem 273 32 20556 20567 10.1074/jbc.273.32.20556 1:CAS:528:DyaK1cXlsVWgu70%3D 9685413 (Pubitemid 28377626)
29. C. P. Rusconi E. Scardino J. Layzer, et al. 2002 RNA aptamers as reversible antagonists of coagulation factor IXa Nature. 419 6902 90 94 10.1038/nature00963 1:CAS:528:DC%2BD38XmslahtLk%3D 12214238 (Pubitemid 34987876)
30. H. Sasaki T. Kojima S. Matsui, et al. 1987 Interaction of lymphocytes with hepatocytes containing hepatitis B antigen: ultrastructural demonstration of target antigen andT-cell subsets by the peroxidase antibody technique Virchows Arch A Pathol Anat Histopathol 411 489 498 10.1007/BF00735232 1:STN:280:DyaL1c%2FhvFWltw%3D%3D 3116764
31. D. Shu P. Guo 2003 A viral RNA that binds ATP and contains a motif similar to an ATP-binding aptamer from SELEX J Biol Chem 278 9 7119 7125 10.1074/jbc.M209895200 1:CAS:528:DC%2BD3sXhsVKis7c%3D 12444088 (Pubitemid 36800709)
32. K. Simon V. R. Lingappa D. Ganem 1988 Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor J Cell Biol 107 2163 2168 10.1083/jcb.107.6.2163 1:CAS:528:DyaL1cXmt1Knur4%3D 3198683 (Pubitemid 19015095)
33. Y. Tian N. Adya S. Wagner, et al. 1995 Dissecting protein:protein interactions between transcription factors with an RNA aptamer RNA 1 3 317 326 1:CAS:528:DyaK2MXmtFelt70%3D 7489503
34. C. Tuerk L. Gold 1990 Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 4968 505 510 10.1126/science.2200121 1:CAS:528:DyaK3cXlt1OltLY%3D 2200121
35. S. R. Watson Y. F. Chang D. O'Connell, et al. 2000 Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo Antisense Nucleic Acid Drug Dev 10 2 63 75 1:CAS:528:DC%2BD3cXivVKlt7s%3D 10805157
36. T. W. Wiegand P. B. Williams S. C. Dreskin, et al. 1996 High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I J Immunol 157 1 221 230 1:STN:280:DyaK283msVKqtg%3D%3D 8683119
37. T. L. Wright 2006 Introduction to chronic hepatitis B infection Am J Gastroenterol 101 S1 S6 10.1111/j.1572-0241.2006.00469.x 16448446 (Pubitemid 43381694)